Press

Innovation1 Biotech Appoints Frederick E. Pierce, II to its Board of Directors

Sep 16 • 4 min read

Innovation1 Biotech Inc. (OTCQB: IVBT), a small molecule drug discovery company focused on the clinical development of modified Schedule 1 molecules of botanical origin, today announced the appointment of Frederick E. Pierce, II, to its Board of Directors. Mr. Pierce is a serial biotech entrepreneur with more than 20 years of senior leadership and operating experience in building…

Blackhawk’s MindBio Therapeutics Announces Reveal Date for Presentation of Phase 1 Clinical Trial Data

Sep 15 • 3 min read

Blackhawk Growth Corp. (CSE:BLR | Frankfurt:0JJ) is pleased to announce that its wholly-owned subsidiary, MindBio Therapeutics, will be presenting its Phase 1 clinical trial data from its LSD (Lysergic Acid Diethylamide) Microdosing studies in Miami on November 4th 2022 at the Wonderland Convention, the world’s largest psychedelics event. MindBio is a clinical stage drug development company creating a safe…

HealingMaps Announces $1 Million in Seed Funding to Power Growth in Psychedelic Therapy Industry

Sep 15 • 3 min read

HealingMaps, an informative and trusted psychedelic therapy search site announced today the close of $1 Million USD in seed round funding from eight investors. The round was led by Phyto Partners along with Ambria Capital. As part of the investment, Cody Shandraw, Managing Partner of Ambria Capital and Phyto Partners will take on the role…

Nova Mentis Completes Production of Psilocybin Microdose Capsules

Sep 15 • 3 min read

Nova Mentis Life Science Corp. (CSE: NOVA | FSE: HN3QO | TCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has completed production of psilocybin microdose capsules in collaboration with the Toronto Institute of Pharmaceutical Technology. TIPT and NOVA have recently completed…

Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

Sep 15 • 2 min read

Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it will effect a 1-for-50 reverse split of its common stock in preparation for the planned listing of the Company’s securities on The Nasdaq Capital Market (“Nasdaq”). The reverse stock split will become effective at…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441